WASHINGTON, Aug 13 (Reuters) - The U.S. Food and Drug Administration said on Wednesday it has approved a new insomnia drug made by Merck & Co..
The drug, to be called Belsomra, is the first in a new class of sedatives that block chemicals in the brain called orexins that help keep people awake.
Belsomra, known generically as suvorexant, has the potential to cause next-day sleepiness and impaired driving.
The FDA approved the drug in four different strengths, with 20 milligrams being the maximum. (Reporting by Toni Clarke; Editing by Sandra Maler)